http://www.fpnotebook.com/
Oral HypoglycemicAka: Oral Medications for Type 2 Diabetes
- Agents: Most effective
- Obese patients
- Thiazolidinediones (e.g. Rosiglitazone)
- Metformin (Glucophage)
- Lean patients
- Sulfonylurea or other secretagogue
- Agents: Available
- General
- Lifestyle changes can lower A1C by 1-2%
- Efficacy Example: Weight loss, diet and Exercise
- Pre-intervention: HBA1C is 10%
- Post-intervention: HBA1C might drop to 8-9%
- Insulin is very cost effective (consider early)
- Lowers HBA1C an unlimited amount
- Can be used with Insulin Resistance agents
- Thiazolidinediones (e.g. Rosiglitazone)
- Metformin (Glucophage)
- Cost (monthly)
- Basal Insulins: NPH ($25) or Lantus ($80)
- Bolus Insulins: Regular ($35) or Lispro ($85)
- Insulin Secretagogues (early Type II Diabetes)
- Older agents (rarely used in United States)
- Chromium Picolinate
- First Generation Sulfonylurea (e.g. Tolbutamide)
- Newer Agents
- Second Generation Sulfonylurea (e.g. Glipizide)
- Cost: $11 per month
- Lowers HBA1C by 1.5%
- Meglitinides (e.g. Nateglinide, Repaglinide)
- Lowers HBA1C by 1.5%
- Insulin Resistance Agents
- Biguanides (e.g. Glucophage)
- Decreases hepatic glucose release
- Lowers HBA1C by 1.5%
- Cost: $45 per month
- Thiazolidinediones (e.g. Rosiglitazone)
- Increases muscle and fat Insulin sensitivity
- May also independently reduce cardiovascular risk
- Lowers HBA1C by up to 1.4%
- Cost: $180 per month
- Alpha-glucosidase inhibitors (e.g. Acarbose)
- Decreases gastrointestinal carbohydrate absorption
- Lowers HBA1C by 0.5 to 1%
- Combination agents
- Glucophage and Insulin secretogogue (e.g. Glucovance)
- Thiazolidinediones with Insulin secretogogue
- Basal Insulin (e.g. Lantus) with Glucophage
- Cost: $125/month
- Contrast Glucophage + Glitizone + Glipizide: $300
- Insulin with Glucophage and Glitazone
- Protocol: Sample Template for Prescribing Combination Oral Agents
- General
- Use a combination of agents (consider from onset)
- Treat Insulin Resistance and Insulin shortage
- Example of oral hypoglycemic regimen for obese patient
- Initial Management: Decrease hepatic glucose release
- Glucophage (Metformin)
- Next Management: Insulin Secretion
- Recent onset Type II Diabetes: Sulfonylurea
- Prolonged Type II Diabetes: Consider Insulin
- Next Management: Insulin Resistance
- Thiazolidinediones (e.g. Rosiglitazone) or
- Alpha-glucosidase inhibitor: (e.g. Acarbose)
- Example of oral hypoglycemic regimen for lean patient
- Initial Management: Insulin Secretion
- Recent onset Type II Diabetes: Sulfonylurea
- Prolonged Type II Diabetes: Consider Insulin
- Next Management
- Alpha-glucosidase inhibitor: (e.g. Acarbose)
- Examples based on timing of hyperglycemia
- Pre-meal fasting hyperglycemia
- Sulfonylurea (most effect is on pre-meal glucose)
- Insulin Resistance agents
- Glucophage (Metformin)
- Thiazolidinediones (e.g. Rosiglitazone)
- Postprandial hyperglycemia (Insulin deficiency)
- Meglitinides (e.g. Repaglinide)
- Alpha-glucosidase inhibitors
- Adverse Effects: Oral Agents
- Hypoglycemia
- Associated with Diabetics on ACE Inhibitors
- Higher risk with Captopril than Enalapril
- Higher risk for Sulfonylureas
- May account for 14% DM admissions for Hypoglycemia
- Weight gain
- Sulfonylureas
- Gastrointestinal side effects
- Biguanides (Glucophage)
- Alpha-glucosidase inhibitors (Acarbose, Miglitol)
- Lactic Acidosis
- Biguanides (Glucophage)
- Liver toxicity
- Thiazolidinediones (e.g. Actos or Avandia)
- Edema (avoid in Congestive Heart Failure)
- Thiazolidinediones (e.g. Actos or Avandia)
- References
- Luna (2001) Am Fam Physician 63(9):1747
- Yki-Jarvinen (2001) 24:758
Navigation Tree